(24.10.2006) Evolva Biotech SA, part of SEED Capital's portfolio, has been awarded USD 26.7 million from the United States Threat Reduction Agency for two drug development programs.

The funding provided will be used over a five-year period to identify and develop novel drug compounds with the aim of filling Investigational New Drug applications to the regulatory authorities.

Prior to this latest collaboration, Evolva Biotech developed the patented Watchmaker technology. This technology captures nature's genetic chemistry pool and combines it with an evolutionary process leading to discovery and optimization of novel small molecules for therapeutic targets.

The Defense Threat Reduction Agency supports a defense program focused on the counteraction of weapons of mass destruction through vaccine programs, and other non-aggressive initiatives for protection against threats to the United States of America and its allies.

Visit our portfolio description of Evolva Biotech SA

More information:

www.evolvabio.com  and www.dtra.mil

For further information, please contact:

Carsten Schou, Partner

cs@seedcapital.dk 

 Phone: +45 39179413

(Published: 24 November 2006)